Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Oncternal Therapeutics Inc (ONCT)

Oncternal Therapeutics Inc (ONCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Oncternal Therapeutics Inc 12230 EL CAMINO REAL SUITE 230 SAN DIEGO CA 92130 USA

www.oncternal.com P: 858-434-1113 F: 858-408-3010

Description:

Oncternal Therapeutics Inc. is a clinical-stage oncology company. It is engaged in developing treatments for cancers with critical unmet medical need. The company's pipeline includes cirmtuzumab, TK-216 and CAR-T therapy that targets ROR1 which are in clinical stage. Oncternal Therapeutics Inc., formerly known as GTx Inc., is based in San Diego, California.

Key Statistics

Overview:

Market Capitalization, $K 23,127
Enterprise Value, $K 16,427
Shares Outstanding, K 2,689
Annual Sales, $ 790 K
Annual Net Income, $ -39,480 K
Last Quarter Sales, $ 300 K
Last Quarter Net Income, $ -9,160 K
EBIT, $ -41,720 K
EBITDA, $ -43,350 K
60-Month Beta 1.26
% of Insider Shareholders 8.00%
% of Institutional Shareholders 16.05%
Float, K 2,474
% Float 92.00%
Short Volume Ratio 0.75

Growth:

1-Year Return 29.42%
3-Year Return -93.02%
5-Year Return -94.45%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 94.18%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -3.11 on 03/07/24
Latest Earnings Date 05/02/24
Earnings Per Share ttm -13.51
EPS Growth vs. Prev Qtr 8.53%
EPS Growth vs. Prev Year 22.25%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-20 on 01/08/24

ONCT Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -95.87%
Return-on-Assets % -83.56%
Profit Margin % -4,997.47%
Debt/Equity 0.00
Price/Sales 30.66
Price/Cash Flow N/A
Price/Book 0.85
Book Value/Share 10.19
Interest Coverage -2.10
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar